Data Bytes: Kymera-Sanofi deal is latest sign targeted degradation is growing up

Kymera and Sanofi’s deal brings the targeted protein degradation space its largest disclosed upfront and most advanced partnered asset to date.

The companies announced Thursday that Sanofi (Euronext:SAN; NASDAQ:SNY) will pay Kymera Therapeutics Inc. $150 million upfront

Read the full 366 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE